Bionomics Of Australia To Add Phase II Trial For Unique Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Bionomics said it would conduct a second Phase II trial of its BNC105 drug for treating mesothelioma cancer, known primarily to be associated with asbestos